BMEA — Biomea Fusion, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1840439 ·
Last close
$1.59
Market Cap
$115.25M
52W High
$1.77
52W Low
$1.10
ADV30
873,050
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -12,766,000 | -8,328,000 | 36,873,000 | 34,824,000 | 24,736,000 |
| Mar 2026 | 0 | — | — | — | 46,385,000 | 44,693,000 | 27,666,000 |
| Dec 2025 | 0 | — | -11,719,000 | 4,612,000 | 58,572,000 | 55,812,000 | 29,020,000 |
| Sep 2025 | 0 | — | -18,600,000 | -16,407,000 | 55,187,000 | 46,642,000 | 39,568,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-47,189,000
Investing CF
$550,000
Financing CF
$25,239,000
CapEx
$-82,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.07
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-469,791,000
Inventory
—
Receivables
$22,000
ST Investments
—
EBIT TTM
$-55,859,000
Pretax Income TTM
$-32,538,000
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -81,307,000 | -61,797,000 | 58,572,000 | 29,020,000 | — | -70,371,000 |
| Dec 2024 | 0 | -144,070,000 | -138,426,000 | 79,938,000 | 28,365,000 | — | -119,894,000 |
| Dec 2023 | 0 | -126,135,000 | -117,255,000 | 199,927,000 | 30,690,000 | — | -96,592,000 |
| Dec 2022 | 0 | -83,634,000 | -81,828,000 | 129,307,000 | 20,768,000 | — | -62,417,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.94
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| COYA | Coya Therapeutics, Inc. | $116.35M | $4.96 | — |
| CPIX | CUMBERLAND PHARMACEUTICALS INC | $117.47M | $7.84 | — |
| RFL | Rafael Holdings, Inc. | $112.16M | $2.19 | — |
| QUCY | Quantum Cyber N.V. | $110.13M | $1.31 | — |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | $121.64M | $4.69 | — |
News headlines (Yahoo Finance, 1h cache)
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
2026-08-24 11:00 · Yahoo
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
2026-08-13 11:00 · Yahoo
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
2026-08-05 20:05 · Yahoo
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
2026-06-05 23:32 · Yahoo
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
2026-06-03 12:00 · Yahoo
Biomea Fusion to Participate at Upcoming Investor Conferences
2026-05-12 20:05 · Yahoo
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
2026-05-11 20:54 · Yahoo
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
2026-05-05 21:50 · Yahoo
Biomea Fusion Status Update: Experts Discuss Icovamenib’s Promise Ahead of ADA 2026
2026-05-05 20:20 · Yahoo
Biomea Fusion Shares Early Type 1 Diabetes Data as COVALENT-112 Shows C-Peptide Gains with Icovamenib
2026-04-28 20:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.